Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab
about
The use of humanized monoclonal antibodies for the prevention of respiratory syncytial virus infectionImpact of respiratory syncytial virus: the nurse's perspectiveProof of principle for epitope-focused vaccine designAnalysis of Human RSV Immunity at the Molecular Level: Learning from the Past and PresentIdentification of common biological pathways and drug targets across multiple respiratory viruses based on human host gene expression analysisHigh throughput screening for small molecule enhancers of the interferon signaling pathway to drive next-generation antiviral drug discoveryRespiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment.GS-5806 Inhibits a Broad Range of Respiratory Syncytial Virus Clinical Isolates by Blocking the Virus-Cell Fusion ProcessWithin-host whole-genome deep sequencing and diversity analysis of human respiratory syncytial virus infection reveals dynamics of genomic diversity in the absence and presence of immune pressureSafety and Effectiveness of Palivizumab in Children at High Risk of Serious Disease Due to Respiratory Syncytial Virus Infection: A Systematic Review.Progress in understanding and controlling respiratory syncytial virus: still crazy after all these yearsMolecular evolution of respiratory syncytial virus fusion gene, Canada, 2006-2010.Increased antibody affinity confers broad in vitro protection against escape mutants of severe acute respiratory syndrome coronavirusStability Characterization of a Vaccine Antigen Based on the Respiratory Syncytial Virus Fusion Glycoprotein.Targeting RSV with vaccines and small molecule drugs.Escape from neutralization by the respiratory syncytial virus-specific neutralizing monoclonal antibody palivizumab is driven by changes in on-rate of binding to the fusion protein.Managing the morbidity associated with respiratory viral infections in children with congenital heart diseaseA review of cost-effectiveness of palivizumab for respiratory syncytial virus.Trivalency of a Nanobody Specific for the Human Respiratory Syncytial Virus Fusion Glycoprotein Drastically Enhances Virus Neutralization and Impacts Escape Mutant Selection.Compassionate use experience with high-titer respiratory syncytical virus (RSV) immunoglobulin in RSV-infected immunocompromised persons.Neutralizing epitopes of RSV and palivizumab resistance in Japan.Preclinical Characterization of PC786, an Inhaled Small-Molecule Respiratory Syncytial Virus L Protein Polymerase Inhibitor.A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants.Targeting Host Cell Surface Nucleolin for RSV Therapy: Challenges and Opportunities.Detection of respiratory syncytial virus fusion protein variants between 2009 and 2012 in China.Respiratory Syncytial Virus (RSV): Targeting the G Protein Provides a New Approach for an Old Problem.Characterization of circulating RSV strains among subjects in the OUTSMART-RSV surveillance program during the 2016-17 winter viral season in the United StatesAntigenic and sequence variability of the human respiratory syncytial virus F glycoprotein compared to related viruses in a comprehensive dataset
P2860
Q26864494-3605CBD2-D6DB-46BF-857A-F229C52366A0Q27023799-F177DC62-F957-466B-B43B-A8AE0D803221Q27681593-24F79E1C-6E75-4094-945D-02F97330C0C7Q28080556-C9DB3DF0-4FED-465F-94D6-0439A1D49DD2Q28481496-650838FE-AE08-4ECD-B850-8E8F37A14242Q28483402-6D5FF17D-F98C-4D06-A496-25FEB3C5D53BQ30240274-BA474048-D1D8-47BC-96F1-5B64FBB47DA7Q30375062-5A07BC78-372F-4901-88A3-B3D65F1FEAFFQ33744060-6C1353E0-4615-4B1E-B7D9-15B808E2061CQ34726169-26355EA1-4011-4DA6-9885-1303BB03480EQ35566601-4A7E0BA1-99FA-4152-8FB5-7ECA7FF2D6A2Q35845854-4FE9A6D5-5FB0-40F4-A715-2363AA733FB6Q36154930-662A76A8-B60A-4096-A88A-9C899B47698EQ36169170-CD942DA9-9872-4322-BF58-8CA2E642D749Q37328584-0AB958F2-5AE1-4976-B567-3C38032243FFQ37732535-F3D20A72-99E8-4B11-AB5A-C4AC66FD0F73Q38003985-E13CA9AC-879E-4582-96CA-848E22676E25Q38058838-6F61C309-5828-4ADC-BF18-346C5355C171Q38750689-205A9190-F32E-4E5F-9F54-CD9C1E1B44C9Q39038875-CAC63FF3-83A2-4129-8225-D4F1AFD19957Q40059727-96E40634-9A33-4AEB-BD04-58497FADEF28Q40144736-9904B9B6-A2A1-444B-9564-EA0E17864A0BQ40216493-58430114-ABD0-417D-94EA-03FFA43CDB86Q41813514-EA5B3590-506A-4896-B55C-056F628C79AEQ42251545-152B9B0B-F39F-4ABA-A950-A29D8B94D550Q45325102-DEC98567-9B36-489C-9285-57BFD801C232Q56967587-82383569-B5CA-47B3-85D1-453E979D7D1FQ57189137-F81809BB-FB38-4C60-97FD-27D98950D2E2
P2860
Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
Analysis of respiratory syncyt ...... palivizumab and/or motavizumab
@ast
Analysis of respiratory syncyt ...... palivizumab and/or motavizumab
@en
Analysis of respiratory syncyt ...... palivizumab and/or motavizumab
@nl
type
label
Analysis of respiratory syncyt ...... palivizumab and/or motavizumab
@ast
Analysis of respiratory syncyt ...... palivizumab and/or motavizumab
@en
Analysis of respiratory syncyt ...... palivizumab and/or motavizumab
@nl
prefLabel
Analysis of respiratory syncyt ...... palivizumab and/or motavizumab
@ast
Analysis of respiratory syncyt ...... palivizumab and/or motavizumab
@en
Analysis of respiratory syncyt ...... palivizumab and/or motavizumab
@nl
P2093
P2860
P356
P1476
Analysis of respiratory syncyt ...... palivizumab and/or motavizumab
@en
P2093
Brandon Liang
Chin-fen Yang
Frances J Palmer-Hill
Genevieve A Losonsky
JoAnn A Suzich
Josie M McAuliffe
Leslie Wachter
Michael P McCarthy
Nita K Patel
P2860
P304
P356
10.1093/INFDIS/JIQ100
P407
P577
2011-01-05T00:00:00Z